At an 'in­flec­tion point': Gen­tiBio reels in $157M ahead of what CEO Adel Na­da sees as a Treg boom

4 years ago
Financing

Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

4 years ago
R&D
FDA+

Keytru­da keeps ex­pand­ing with an­oth­er pri­or­i­ty re­view; Medicxi-backed eye drop mak­er wins new fund­ing, re­gion­al deal

4 years ago
News Briefing

A Cana­di­an start­up re­fu­els to take on a rare car­diac con­di­tion that many pa­tients don't re­al­ize they have

4 years ago
Financing

Paragon's Har­mo­ny Bio­sciences brings in $330M of debt cap­i­tal and eq­ui­ty, look­ing to ex­pand nar­colep­sy drug la­bel

4 years ago
Financing

Mod­er­na strikes a deal with Cana­da to build an mR­NA man­u­fac­tur­ing cen­ter — and it’s look­ing for more glob­al pacts ...

4 years ago
Coronavirus
Manufacturing

BioN­Tech ex­pects to be $18.6B rich­er af­ter this year as Covid boost­ers churn out more da­ta. But it won't change much

4 years ago
Pharma
Coronavirus

Mod­er­na soars in­to the ranks of the world's top phar­ma play­ers, now worth 3 Re­gen­erons

4 years ago
Bioregnum
Pharma

Covid-19 roundup: New study sug­gests Mod­er­na vac­cine may be more ef­fec­tive than Pfiz­er against the Delta vari­ant; ...

4 years ago
Coronavirus

Vir­tu­al­ly un­known mR­NA up­start rides SPAC to Nas­daq with a $1.5B val­u­a­tion as RA-backed neu­ro play­er prices IPO

4 years ago
Financing

Gilead joins the move­ment to man­date staff vac­ci­na­tions against Covid-19. And it looks like the rest of the in­dus­try ...

4 years ago
Pharma

A decades-old glau­co­ma drug tossed aside by Pfiz­er gets a new life at a small biotech

4 years ago
People
Deals

For­mer BAR­DA di­rec­tor set­tles whistle­blow­er case on Trump's mis­man­age­ment of the pan­dem­ic

4 years ago
People
Coronavirus

Ab­b­Vie hands over $20M for Alzheimer's, Parkin­son's drugs; Au­to­lus boost­ed by a PIM

4 years ago
News Briefing

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

4 years ago
Deals
China

Covid-19 roundup: Fau­ci pre­dicts more man­dates fol­low­ing full vac­cine ap­proval; AAP tells FDA to au­tho­rize vac­cines ...

4 years ago
Coronavirus

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

4 years ago
Deals
Pharma

Bi­o­Life So­lu­tions sets up shop in In­di­anapo­lis, adding a slate of new cell and gene ther­a­py tools to its belt

4 years ago
Deals
Cell/Gene Tx

Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash ...

4 years ago
R&D
Cell/Gene Tx

Let­ter from FDA out­lin­ing de­fi­cien­cies for lead drug caus­es Ax­some stock to crater. Is a CRL on the way?

4 years ago
R&D
Pharma

On a quest to treat new­ly di­ag­nosed lym­phoma pa­tients, Roche teas­es pos­i­tive piv­otal da­ta

4 years ago
R&D

8 ways Chi­na could help trans­form the glob­al bio­phar­ma in­dus­try

4 years ago
Biotech Voices

Robert Baze­more inks one last deal for Epizyme — adding Chi­na to Tazverik's glob­al blue­print — be­fore head­ing out ...

4 years ago
Deals
China

As­traZeneca and Dai­ichi Sankyo con­tin­ue to flesh out En­her­tu plans, claim­ing win in ear­li­er breast can­cer line

4 years ago
R&D
First page Previous page 664665666667668669670 Next page Last page
A service from the Financial Times